Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

perjantai 9. maaliskuuta 2018 päivittänyt: GlaxoSmithKline

A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212 to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV malignant cutaneous melanoma. All subjects must have a BRAF mutation-positive tumour sample. Subjects who have received up to one prior regimen of chemotherapy in the advanced or metastatic melanoma setting will be enrolled into the study. Subjects with any prior BRAF or MEK inhibitor use will be excluded. Approximately 297 subjects will be enrolled with 2:1 randomization (198 subjects into the GSK1120212 arm and 99 subjects into the chemotherapy arm). The primary endpoint for the statistical analysis will be a comparison of progression free survival for subjects receiving GSK1120212 compared to chemotherapy. Subjects who have progression on chemotherapy will be offered the option to receive GSK1120212.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

322

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Argentiina
      • Ciudad Autonoma de Buenos Aires, Argentiina, C1121ABE
        • GSK Investigational Site
  • Australia
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2606
        • GSK Investigational Site
    • New South Wales
      • Port Macquarie, New South Wales, Australia, 2444
        • GSK Investigational Site
      • Waratah, New South Wales, Australia, 2300
        • GSK Investigational Site
    • Queensland
      • South Brisbane, Queensland, Australia, 4101
        • GSK Investigational Site
      • Townsville, Queensland, Australia, 4810
        • GSK Investigational Site
      • Woolloongabba, Queensland, Australia, 4102
        • GSK Investigational Site
    • South Australia
      • Kurralta Park, South Australia, Australia, 5037
        • GSK Investigational Site
      • Woodville, South Australia, Australia, 5011
        • GSK Investigational Site
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • GSK Investigational Site
      • Melbourne, Victoria, Australia, 3004
        • GSK Investigational Site
  • Belgia
      • Brussels, Belgia, 1200
        • GSK Investigational Site
      • Charleroi, Belgia, 6000
        • GSK Investigational Site
      • Gent, Belgia, 9000
        • GSK Investigational Site
      • Jette, Belgia, 1090
        • GSK Investigational Site
      • Kortrijk, Belgia, 8500
        • GSK Investigational Site
      • Leuven, Belgia, 3000
        • GSK Investigational Site
      • Wilrijk, Belgia, 2610
        • GSK Investigational Site
      • Yvoir, Belgia, 5530
        • GSK Investigational Site
  • Italia
    • Lombardia
      • Milano, Lombardia, Italia, 20132
        • GSK Investigational Site
      • Milano, Lombardia, Italia, 20133
        • GSK Investigational Site
      • Milano, Lombardia, Italia, 20141
        • GSK Investigational Site
    • Toscana
      • Pisa, Toscana, Italia, 56126
        • GSK Investigational Site
  • Itävalta
      • Graz, Itävalta, 8036
        • GSK Investigational Site
      • Wien, Itävalta, 1090
        • GSK Investigational Site
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
        • GSK Investigational Site
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 4E6
        • GSK Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
        • GSK Investigational Site
    • Ontario
      • Hamilton, Ontario, Kanada, L8V 5C2
        • GSK Investigational Site
      • London, Ontario, Kanada, N6A 4L6
        • GSK Investigational Site
      • Oshawa, Ontario, Kanada, L1G 2B9
        • GSK Investigational Site
      • Ottawa, Ontario, Kanada, K1H 8L6
        • GSK Investigational Site
      • Toronto, Ontario, Kanada, M5G 2M9
        • GSK Investigational Site
    • Quebec
      • Montreal, Quebec, Kanada, H2L 4M1
        • GSK Investigational Site
      • Montreal, Quebec, Kanada, H2W 1S6
        • GSK Investigational Site
  • Kreikka
      • Athens, Kreikka, 11527
        • GSK Investigational Site
      • Athens, Kreikka, 185 47
        • GSK Investigational Site
      • Thessaloniki, Kreikka, 564 29
        • GSK Investigational Site
  • Norja
      • Oslo, Norja, 0310
        • GSK Investigational Site
  • Puola
      • Poznan, Puola, 61-866
        • GSK Investigational Site
      • Warszawa, Puola, 02-781
        • GSK Investigational Site
      • Warszawa, Puola, 04-125
        • GSK Investigational Site
  • Ranska
      • Boulogne-Billancourt, Ranska, 92100
        • GSK Investigational Site
      • Grenoble, Ranska, 38043
        • GSK Investigational Site
      • Montpellier, Ranska, 34295
        • GSK Investigational Site
      • Nantes, Ranska, 44093
        • GSK Investigational Site
      • Paris Cedex 10, Ranska, 75475
        • GSK Investigational Site
      • Pierre-Benite cedex, Ranska, 69495
        • GSK Investigational Site
      • Rennes, Ranska, 35042
        • GSK Investigational Site
      • Tours, Ranska, 37044
        • GSK Investigational Site
      • Villejuif, Ranska, 94805
        • GSK Investigational Site
  • Ruotsi
      • Goteborg, Ruotsi, SE-413 45
        • GSK Investigational Site
      • Linkoping, Ruotsi, SE-581 85
        • GSK Investigational Site
      • Lund, Ruotsi, SE-221 85
        • GSK Investigational Site
      • Stockholm, Ruotsi, SE-171 76
        • GSK Investigational Site
      • Uppsala, Ruotsi, SE-751 85
        • GSK Investigational Site
  • Saksa
      • Berlin, Saksa, 10117
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Heidelberg, Baden-Wuerttemberg, Saksa, 69120
        • GSK Investigational Site
      • Mannheim, Baden-Wuerttemberg, Saksa, 68167
        • GSK Investigational Site
      • Tuebingen, Baden-Wuerttemberg, Saksa, 72076
        • GSK Investigational Site
    • Bayern
      • Muenchen, Bayern, Saksa, 80804
        • GSK Investigational Site
      • Wuerzburg, Bayern, Saksa, 97080
        • GSK Investigational Site
    • Niedersachsen
      • Buxtehude, Niedersachsen, Saksa, 21614
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Essen, Nordrhein-Westfalen, Saksa, 45122
        • GSK Investigational Site
    • Sachsen
      • Dresden, Sachsen, Saksa, 01307
        • GSK Investigational Site
    • Schleswig-Holstein
      • Luebeck, Schleswig-Holstein, Saksa, 23538
        • GSK Investigational Site
  • Sveitsi
      • Zurich, Sveitsi, 8091
        • GSK Investigational Site
  • Tšekki
      • Hradec Kralove, Tšekki, 500 05
        • GSK Investigational Site
      • Ostrava, Tšekki, 708 52
        • GSK Investigational Site
      • Praha 2, Tšekki, 128 08
        • GSK Investigational Site
      • Zlin, Tšekki, 76275
        • GSK Investigational Site
  • Ukraina
      • Dnepropetrovsk, Ukraina, 49102
        • GSK Investigational Site
      • Kharkiv, Ukraina, 61070
        • GSK Investigational Site
      • Kyiv, Ukraina, 03022
        • GSK Investigational Site
      • Kyiv, Ukraina, 03115
        • GSK Investigational Site
      • Lviv, Ukraina, 79031
        • GSK Investigational Site
      • Sumy, Ukraina, 40005
        • GSK Investigational Site
      • Sympheropol, Ukraina, 95023
        • GSK Investigational Site
      • Ternopil, Ukraina, 46023
        • GSK Investigational Site
      • Uzhgorod, Ukraina, 88017
        • GSK Investigational Site
  • Uusi Seelanti
      • Christchurch, Uusi Seelanti, 8011
        • GSK Investigational Site
      • Dunedin, Uusi Seelanti, 9016
        • GSK Investigational Site
      • Newtown, Wellington, Uusi Seelanti, 6002
        • GSK Investigational Site
  • Venäjän federaatio
      • Chelyabinsk, Venäjän federaatio, 454087
        • GSK Investigational Site
      • Magnitogorsk, Venäjän federaatio, 455001
        • GSK Investigational Site
      • Moscow, Venäjän federaatio, 115478
        • GSK Investigational Site
      • St. Petersburg, Venäjän federaatio, 197758
        • GSK Investigational Site
  • Yhdistynyt kuningaskunta
      • Aberdeen, Yhdistynyt kuningaskunta, AB25 2ZN
        • GSK Investigational Site
      • Birmingham, Yhdistynyt kuningaskunta, B15 2TH
        • GSK Investigational Site
      • Chelmsford, Yhdistynyt kuningaskunta, CM1 7ET
        • GSK Investigational Site
      • Leeds, Yhdistynyt kuningaskunta, LS9 7TF
        • GSK Investigational Site
      • London, Yhdistynyt kuningaskunta, SW3 6JJ
        • GSK Investigational Site
      • London, Yhdistynyt kuningaskunta, W1G 6AD
        • GSK Investigational Site
      • Manchester, Yhdistynyt kuningaskunta, M20 4BX
        • GSK Investigational Site
      • Oxford, Yhdistynyt kuningaskunta, OX3 7LJ
        • GSK Investigational Site
      • Southampton, Yhdistynyt kuningaskunta, SO16 6YD
        • GSK Investigational Site
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Yhdistynyt kuningaskunta, CB2 2QQ
        • GSK Investigational Site
    • Middlesex
      • Northwood, Middlesex, Yhdistynyt kuningaskunta, HA6 2RN
        • GSK Investigational Site
    • Surrey
      • Sutton, Surrey, Yhdistynyt kuningaskunta, SM2 5PT
        • GSK Investigational Site
  • Yhdysvallat
    • Arizona
      • Tucson, Arizona, Yhdysvallat, 85724-5024
        • GSK Investigational Site
    • Florida
      • Fort Myers, Florida, Yhdysvallat, 33916
        • GSK Investigational Site
    • Georgia
      • Athens, Georgia, Yhdysvallat, 30607
        • GSK Investigational Site
      • Marietta, Georgia, Yhdysvallat, 30060
        • GSK Investigational Site
    • Iowa
      • Iowa City, Iowa, Yhdysvallat, 52242
        • GSK Investigational Site
    • Louisiana
      • Metairie, Louisiana, Yhdysvallat, 70006
        • GSK Investigational Site
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02114
        • GSK Investigational Site
    • New Jersey
      • Morristown, New Jersey, Yhdysvallat, 07962-1956
        • GSK Investigational Site
    • Ohio
      • Columbus, Ohio, Yhdysvallat, 43210
        • GSK Investigational Site
    • South Carolina
      • Columbia, South Carolina, Yhdysvallat, 29210
        • GSK Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, Yhdysvallat, 37404
        • GSK Investigational Site
      • Memphis, Tennessee, Yhdysvallat, 38120
        • GSK Investigational Site
      • Nashville, Tennessee, Yhdysvallat, 37203
        • GSK Investigational Site

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • ≥18 years of age
  • Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
  • Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
  • Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  • Adequate screening organ function

Exclusion Criteria:

  • Any prior use of BRAF inhibitors or MEK inhibitors.
  • Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
  • History of another malignancy. Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
  • Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
  • Brain metastases with the following exceptions that are ALL confirmed by the GSK Medical Monitor:

All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to randomization (must be documented with two consecutive MRI or CT scans using contrast), and asymptomatic with no corticosteroids requirement for ≥ 30 days prior to randomization, and no enzyme-inducing anticonvulsants for ≥ 30 days prior to randomization

  • History or evidence of cardiovascular risk including any of the following:

    • QTcB ≥ 480 msec.
    • History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible
    • History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
    • History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association
  • History of interstitial lung disease or pneumonitis

  • History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):

    • History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes).
    • Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
  • Evidence of new optic disc cupping.
  • Intraocular pressure > 21 mm Hg as measured by tonography

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: GSK1120212
MEK inhibitor
Lääke: GSK1120212
MEK-inhibiittori
Active Comparator: Chemotherapy
Investigator Choice of DTIC or paclitaxel
Lääke: Chemotherapy
Investigator Choice of DTIC or paclitaxel
Kokeellinen: Crossover
MEK inhibitor after documented progression on Chemotherapy Arm
Lääke: GSK1120212
MEK-inhibiittori

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death. PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Progression-free Survival in All Participants
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed and BRIC-assessed PFS were summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. Intend-To-Treat (ITT) Population included all randomized participants regardless of whether or not treatment was administered.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death. Investigator-assessed PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Overall Survival in All Participants
Aikaikkuna: Day 1 until death due to any cause (average of 20.3 months)
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
Day 1 until death due to any cause (average of 20.3 months)
Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases
Aikaikkuna: Day 1 until death due to any cause (average of 20.3 months)
Overall survival was defined as the time from the date of randomization to the date of death due to any cause. NA indicates data was not available.
Day 1 until death due to any cause (average of 20.3 months)
Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of Participants With OR as Assessed by the Investigator and Independent Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (disappearance of all extranodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all extranodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of Participants With OR Following Cross-over to Trametinib
Aikaikkuna: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
OR is defined as the number of participants with evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib. The evaluation was carried out by the Investigator per RECIST, Version 1.1. Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT. Only participants who received at least one dose of Trametinib were included in this population.
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause. DoR for the investigator-assessed (INVA) response data were summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause. DoR for the independently-assessed (INDA) response data were summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR for the INVA response data was summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review
Aikaikkuna: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR for the INDA response data was summarized per RECIST, Version 1.1. Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator
Aikaikkuna: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
PFS Following Cross-over to Trametinib as Assessed by the Investigator
Aikaikkuna: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death. PFS was summarized per RECIST, Version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

GlaxoSmithKline

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 22. marraskuuta 2010

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 26. lokakuuta 2011

Opintojen valmistuminen (Todellinen)

Perjantai 16. joulukuuta 2016

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 18. marraskuuta 2010

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 18. marraskuuta 2010

Ensimmäinen Lähetetty (Arvio)

Maanantai 22. marraskuuta 2010

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 5. huhtikuuta 2018

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 9. maaliskuuta 2018

Viimeksi vahvistettu

Maanantai 1. tammikuuta 2018

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • 114267

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Kliiniset tutkimukset GSK1120212

Hae vastaavia kokeiluja

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

CROs by country

CROs in Mauritius

Ehdot

Harvinaiset sairaudet

Huumeiden interventiot

Ravintolisät

Sponsori / yhteistyökumppanit

Sijainnit

3
Tilaa